ExoDiscovery
- Diagnostics
- Medical device or technology
- Other R&D services
- Synthesis, analytic, diagnostic services
- Biotech or pharma, therapeutic R&D
Unprecedented sensitivity for detection and monitoring of lung and pancreatic cancers with a simple blood test. Combating cancer with dynamic monitoring and diagnostics based on revolutionary exosome fusion technology. NGS or PCR is not needed. ExoDiscovery has developed an ultra-sensitive, rapid, and cost effective blood test for lung and pancreatic cancer which will launch commercially in Q4 2025. Biomarkers in exosomes are the next frontier of diagnostics given their unique sensitivity to detect cancer, and ExoDiscovery is at the forefront.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}